FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 348:1705-1708 April 24, 2003 Number 17 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Jonsson, K. B. PubMed Citation

Oncogenic osteomalacia has fascinated physiology-minded physicians for decades. The traditional name for this peculiar disorder connotes its classification as a paraneoplastic phenomenon. Such a characterization is a bit off the mark, however, in that the involved "neoplasm" is often (but not always) of limited clinical significance apart from its causal role in the musculoskeletal disease. Tumors responsible for oncogenic osteomalacia are usually benign rather than invasive, whereas generalized, debilitating osteomalacia and rickets are the important clinical problems for the patient. The assay for the measurement of circulating levels of fibroblast growth factor 23 (FGF-23), the development of which is described . . . [Full Text of this Article]

Clinical Presentation

Evaluation

Treatment and Course

Pathophysiology and Candidate Mediators

Source Information

From the Section of Pediatric Endocrinology, Yale University School of Medicine, New Haven, Conn.

This article has been cited by other articles:

• Paul, S., Kurtz, M., Mentzer, S. J. (2007). Osteomalacia associated with a fibroblast growth factor 23 secreting chest wall tumor. J. Thorac. Cardiovasc. Surg. 134: 803-805 [Full Text]  
• Hesse, E., Rosenthal, H., Bastian, L. (2007). Radiofrequency Ablation of a Tumor Causing Oncogenic Osteomalacia. NEJM 357: 422-424 [Full Text]  
• Dowman, J K, Khattak, F H (2006). Oncogenic hypophosphataemic osteomalacia mimicking bone metastases on isotope bone scan.. Ann Rheum Dis 65: 1664-1664 [Full Text]  
• Owen, S., Hatfield, A., Letvak, L., Tournis, S., Lyritis, G. P., Joensuu, H., Reichardt, P., Berman, E., Fleisher, M., Sauter, N. P. (2006). Imatinib and altered bone and mineral metabolism.. NEJM 355: 627-627 [Full Text]  
• Ladha, S. S., Whitaker, M. D., Bosch, E. P. (2006). Oncogenic osteomalacia: muscular weakness and multiple fractures.. Neurology 67: 364-365 [Full Text]  
• Carpenter, T. O., Ellis, B. K., Insogna, K. L., Philbrick, W. M., Sterpka, J., Shimkets, R. (2005). Fibroblast Growth Factor 7: An Inhibitor of Phosphate Transport Derived from Oncogenic Osteomalacia-Causing Tumors. J. Clin. Endocrinol. Metab. 90: 1012-1020 [Abstract] [Full Text]  
• Bai, X., Miao, D., Li, J., Goltzman, D., Karaplis, A. C. (2004). Transgenic Mice Overexpressing Human Fibroblast Growth Factor 23 (R176Q) Delineate a Putative Role for Parathyroid Hormone in Renal Phosphate Wasting Disorders. Endocrinology 145: 5269-5279 [Abstract] [Full Text]